Track topics on Twitter Track topics that are important to you
Bristol-Myers Squibb (BMS) will carry out a Phase I/II study assessing both its Opdivo ® (nivolumab) and its Opdivo + Yervoy ® (ipilimumab) regimen in combination with Novartis’ Mekinist ® (trametinib) in metastatic colorectal cancer. The clinical research collaboration—whose value was not disclosed—will entail a study of the safety, tolerability, and efficacy of the combinations in patients with microsatellite stable tumors, where the tumors are proficient in mismatch repair (MSS mCRC pMMR). BMS will conduct the study and is expected to establish recommended dose regimens as well as the preliminary anti-tumor activity of the combination therapies. BMS and Novartis plan to evaluate the results to determine optimal approaches and determine potential clinical development of these combinations. The study marks an expansion of an ongoing partnership by the two pharma giants, launched in 2014 and initially focused on combining cancer treatments of the companies in order to ...
Original Article: BMS, Novartis to Study Combination Therapies for Colorectal CancerNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells. Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...